Literature DB >> 9165405

Do seizures beget seizures? An assessment of the clinical evidence in humans.

A T Berg1, S Shinnar.   

Abstract

For more than a century, epilepsy was characterized as a chronic disease, with little chance of remission or cure. It was also considered a progressive disease in which seizures led to more seizures. Experimental work in animals provided additional support for the notion that seizures could beget seizures. However, the earliest clinical observations in humans were based on highly selected, largely refractory patients. Furthermore, the experimental work in animals bore little relation to naturally occurring seizures and epilepsy in humans. Evidence from multiple sources regarding the nature and natural history of seizures and epilepsy in humans has repeatedly demonstrated that in most cases of occurrence of seizures itself does not influence the long-term outcome of epilepsy. Consequently, interventions to prevent seizures early in the course of a seizures disorder do not alter the natural history of seizure disorders with respect to whether remission will occur in the long term. That outcome is largely predetermined by other factors, many of which are not currently amenable to intervention. In some rare syndromes, deterioration is progressive. In these instances, it is the underlying syndrome, not the seizures, that is primarily responsible for the deterioration. In addition, extremely prolonged seizures (which are rare) may also directly cause damage. These are exceptions rather than, as previously believed, the rule. The available human data strongly suggest that seizures do not beget seizures and that epilepsy in humans is usually not a progressive disorder.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9165405     DOI: 10.1097/00004691-199703000-00003

Source DB:  PubMed          Journal:  J Clin Neurophysiol        ISSN: 0736-0258            Impact factor:   2.177


  18 in total

1.  Febrile Seizures and Mesial Temporal Sclerosis.

Authors:  Shlomo Shinnar
Journal:  Epilepsy Curr       Date:  2003-07       Impact factor: 7.500

2.  Seizures beget seizures: a lack of experimental evidence and clinical relevance fails to dampen enthusiasm.

Authors:  Graeme J Sills
Journal:  Epilepsy Curr       Date:  2007 Jul-Aug       Impact factor: 7.500

3.  Intrinsic severity as a determinant of antiepileptic drug refractoriness.

Authors:  Michael A Rogawski; Michael R Johnson
Journal:  Epilepsy Curr       Date:  2008 Sep-Oct       Impact factor: 7.500

4.  Development of later life spontaneous seizures in a rodent model of hypoxia-induced neonatal seizures.

Authors:  Sanjay N Rakhade; Peter M Klein; Thanthao Huynh; Cristina Hilario-Gomez; Bela Kosaras; Alexander Rotenberg; Frances E Jensen
Journal:  Epilepsia       Date:  2011-03-02       Impact factor: 5.864

5.  Febrile seizures in the developing brain result in persistent modification of neuronal excitability in limbic circuits.

Authors:  K Chen; T Z Baram; I Soltesz
Journal:  Nat Med       Date:  1999-08       Impact factor: 53.440

Review 6.  Treatment strategies after a single seizure : rationale for immediate versus deferred treatment.

Authors:  Laura C Miller; Frank W Drislane
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 7.  The natural history of epilepsy: an epidemiological view.

Authors:  P Kwan; J W Sander
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-10       Impact factor: 10.154

Review 8.  Computer modelling of epilepsy.

Authors:  William W Lytton
Journal:  Nat Rev Neurosci       Date:  2008-07-02       Impact factor: 34.870

9.  Prolonged febrile seizures in the immature rat model enhance hippocampal excitability long term.

Authors:  C Dube; K Chen; M Eghbal-Ahmadi; K Brunson; I Soltesz; T Z Baram
Journal:  Ann Neurol       Date:  2000-03       Impact factor: 10.422

10.  NMDA receptor-mediated long-term alterations in epileptiform activity in experimental chronic epilepsy.

Authors:  Jennifer L Hellier; Andrew White; Philip A Williams; F Edward Dudek; Kevin J Staley
Journal:  Neuropharmacology       Date:  2008-10-07       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.